A study of Acalabrutinib suspension to evaluate relative bioavailability and proton-pump inhibitor effect in healthy volunteers

Trial Identifier: D822FC00004
Sponsor: AstraZeneca
Collaborator:
Acerta Pharma
NCTID:: NCT04435483
Start Date: May 2020
Primary Completion Date: June 2020
Study Completion Date: June 2020
Condition: Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English version

Trial Locations

Country Location
United States of America, CA Glendale, CA, United States of America, 91206